Drug intelligence / Profile preview

vrtx153

Development stage: Preclinical
Lead developer: VRise Therapeutics
Modality: Small Molecules

Overview

VRTX153 is a small molecule inhibitor targeting the KRAS G12D mutation, which is a common oncogenic driver in several solid tumors, most notably pancreatic cancer. The drug acts by inhibiting the GTPase activity of mutant KRAS G12D protein, thereby disrupting downstream signaling pathways that promote tumor growth and survival. VRTX153 is being developed by Vrise Therapeutics and is currently in preclinical development. Its primary indication is pancreatic cancer, but it may also have potential applications in other cancers harboring the KRAS G12D mutation[1][2][3][7].

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on vrtx153.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vrtx153.

Explore the full profile